AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25711262
Drug: i‐gel® (i‐gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i‐gel® (i‐gel)
Trial: 23547511
Drug: Platelet Rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Rich Fibrin (PRF) applied locally (6 ml)
Trial: 19655334
Drug: Polygeline infusion
RxNorm normalized name: polygeline
DrugBank: Polygeline (DB15879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polygeline infusion
Trial: 11872276
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after surgery until tumor progression (Control)
Trial: 9672056
Drug: Pharmacotherapy (nortriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (nortriptyline hydrochloride)
Trial: 9672056
Drug: Pharmacotherapy relative
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy relative to usual care
Trial: 7601178
Drug: Topical NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical NSAID felbinac
Trial: 7601178
Drug: Oral NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NSAIDs (ibuprofen, fenbufen)
Trial: 28737627
Drug: PHiD‐CV10 (10-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD‐CV10 (10-valent pneumococcal conjugate vaccine)
Trial: 23283428
Drug: Simvastatin 3
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 3 mg/kg
Trial: 14987187
Drug: Head-down tilt
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head-down tilt position during physiotherapy treatment
Trial: 14987187
Drug: Flat side-lying
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat side-lying position during physiotherapy treatment
Trial: 14987187
Drug: Physiotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy treatment (both positions)
Trial: 9040032
Drug: Adenosine receptor
RxNorm normalized name: Adenosine receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine receptor stimulation (ADO) trabeculae, 125 micromol/l for 5 min
Trial: 9040032
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of K(ATP) channel with glibenclamide (GLI) trabeculae, 10 micromol/l
Trial: 8164027
Drug: GM2/BCG vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM2/BCG vaccine
Trial: 2500069
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 20 mg of MMC on the day of surgery and 10 mg of MMC the day after surgery, started on tegafur at a dose of 600 mg/day 2 weeks after surgery
Trial: 2500069
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: similarly treated with MMC and started on UFT at a dose of 600 mg/day 2 weeks after surgery
Trial: 1101081
Drug: Vincristine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine and Prednisone reinduction therapy
Trial: 22821424
Drug: Green-lipped mussel
RxNorm normalized name: New Zealand green mussel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green-lipped mussel extract (3,000 mg/day)
Trial: 22821424
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulphate (3,000 mg/day)
Trial: 16521117
Drug: Pycnogenol 30
RxNorm normalized name: Pycnogenol 30 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol 30 mg/day
Trial: 1837550
Drug: Prophylactic teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic teicoplanin (one single bolus intravenous injection before catheter insertion)
Trial: 6124424
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tofisopam
Trial: 6124424
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tofisopam
Trial: 31753032
Drug: EMDR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR therapy (nine sessions, around 60 min each, delivered weekly)
Trial: 31753032
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (routine care)
Trial: 18448211
Drug: Live, oral
RxNorm normalized name: typhoid vaccine, live, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, oral ADV‐4 and ADV‐7 vaccines administered in a single dose to 30 subjects.
Trial: 18448211
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to 28 subjects.
Trial: 17285717
Drug: Silver nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver (DB12965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver nitrate ointment
Trial: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRN) administered by a 1-h i.v. infusion at doses of 20, 24, or 29 mg/m2 daily for 5 consecutive days for 2 weeks.
Trial: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRN) at doses of 20, 24, and 29 mg/m2.
Trial: 10741701
Drug: Irinotecan (IRN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRN) after dose 1.
Trial: 10741701
Drug: Protracted schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted schedule of administration of Irinotecan (IRN).
Trial: 1801155
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of amocarzine once daily (12 patients)
Trial: 1801155
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of amocarzine twice daily (59 patients)
Trial: 30309839
Drug: Lycopene capsule
RxNorm normalized name: Antioxidant Super with Lutein and Lycopene Capsule
DrugBank: Lycopene (DB11231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lycopene capsule (15 mg)
Trial: 30309839
Drug: Active capsule
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active capsule group (EGCG 600 mg)
Trial: 25297016
Drug: Idalopirdine 90
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idalopirdine 90 mg/day (30 mg thrice daily)
Trial: 19320533
Drug: Galantamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine treatment for 6 months
Trial: 17462043
Drug: Bran supplement
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bran supplement with planned nursing interventions
Trial: 16353060
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg) with Indapamide (1.25 mg) (Noliprel forte)
Trial: 16353060
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg) with Hydrochlorothiazide (25 mg) (Capozide)
Trial: 11955727
Drug: Beta-interferon (Betaseron)
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-interferon (Betaseron) 16 x 10(6) IU by i.v. bolus 3 days a week on Weeks 1, 3, and 5, given 30 minutes before radiation therapy.
Trial: 11955727
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) alone, 2 Gy per fraction, 5 days a week, for a total of 60 Gy over 6 weeks.
Trial: 17163255
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1g
Trial: 9708687
Drug: Paracetamol 1g
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1g plus codeine 60 mg
Trial: 2281374
Drug: Rehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation treatment group
Trial: 28368909
Drug: Asacol 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol 2.4 g once daily (QD) for 48 weeks
Trial: 28368909
Drug: Asacol 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol 2.4 g three times daily (TID) for 48 weeks
Trial: 26409291
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab 0.05%
Trial: 16461077
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 20 mg twice daily
Trial: 15290743
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg followed by 200 mg bid
Trial: 16960941
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid
Trial: 11387349
Drug: Zoladex and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex and Tamoxifen in combination (ZT)
Trial: 8448748
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg, four times daily for 3 months)
Trial: 10408635
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (12 mg Zn++/day for one month)
Trial: 10408635
Drug: HAART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART therapy
Trial: 8772215
Drug: Fragmin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (low-molecular-weight heparin) administered subcutaneously at a fixed dose of 120 Anti-Xa IU/kg twice a day for 10 days.
Trial: 8772215
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin administered intravenously.
Trial: 1965113
Drug: Intranasal NPC
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal NPC 567 (bradykinin antagonist)
Trial: 6162471
Drug: L-Tryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Tryptophan (50 mg/kg) administered twice daily for 7 days
Trial: 6162471
Drug: L-Tryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Tryptophan (50 mg/kg) administered either acutely or chronically
Trial: 6321356
Drug: Cefotaxime (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1-2 g b.i.d.)
Trial: 6321356
Drug: Ceftizoxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (2 g b.i.d.)
Trial: 6321356
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g u.i.d.)
Trial: 24643203
Drug: Rotigotine 8
RxNorm normalized name: ROTIGOTINE 8MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 8 mg/24 h
Trial: 24643203
Drug: Rotigotine 8
RxNorm normalized name: ROTIGOTINE 8MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 8 mg/24 h vs Placebo
Trial: 20811078
Drug: Plyometric training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plyometric training (6 weeks, 3 times weekly)
Trial: 17635939
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) users in intervention group
Trial: 12087018
Drug: IA-2 antibody
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-2 antibody positive, GAD antibody negative group
Trial: 2140735
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the supine position
Trial: 2140735
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion at a rate of 0.06 ml/kg/min for 2 h in the seated position
Trial: 2140735
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion in both positions
Trial: 547544
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg 17 beta‐estradiol or 250 mg estriol
Trial: 547544
Drug: gel only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel only (control group)
Trial: 26874388
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical assessment (blind therapy group)
Trial: 22773769
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen replacement therapy (ERT) using Evorel patches
Trial: 22773769
Drug: No patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patch (control period)
Trial: 15093987
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg od
Trial: 11399783
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg) three times daily for 7 days
Trial: 11399783
Drug: Chitosan (890
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (890 mg) three times daily for 7 days
Trial: 9257889
Drug: HD‐CY (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD‐CY (4 g/m2 i.v.) plus GM‐CSF (8 microg/kg/day s.c.)
Trial: 9257889
Drug: G‐CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (10 microg/kg/day s.c.) alone
Trial: 9678793
Drug: G‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF alone
Trial: 31420414
Drug: Pertuzumab (840→420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (840→420 mg every 3 weeks)
Trial: 25795927
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT) for perfectionism
Trial: 21875697
Drug: Subinguinal varicocelectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subinguinal varicocelectomy after 2 ml intratunical space injection of methylene blue
Trial: 19701034
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment (scaling and root planing early in the second trimester)
Trial: 19701034
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (periodontal care after delivery)
Trial: 11422091
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg qd lanepitant
Trial: 8637697
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection at 37 degrees C (body temperature)
Trial: 6378437
Drug: Indomethacin, 25
RxNorm normalized name: Indomethacin, 25 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 25 mg tds
Trial: 6378437
Drug: Aspirin-SR, 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-SR, 650 mg daily
Trial: 6378437
Drug: Paracetamol, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol, 1 g 8th hourly
Trial: 6378437
Drug: Naproxen, 250
RxNorm normalized name: Naproxen, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen, 250 mg mane and 500 mg nocte
Trial: 6378437
Drug: Sulindac, 200
RxNorm normalized name: Sulindac, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac, 200 mg bd
Trial: 24722423
Drug: Jinzhen oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinzhen oral liquid
Trial: 23379201
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.2% (instilled twice-daily)
Trial: 23379201
Drug: Olopatadine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 0.1% (instilled 4-times daily)
Trial: 20199178
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg three times a day (Group 1)
Trial: 20199178
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg and pentoxifylline 400 mg each three times per day (Group 2)
Trial: 11849194
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of 1 g paracetamol
Trial: 11849194
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of paracetamol
Trial: 7737532
Drug: Spectrotypic analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectrotypic analysis of antibody response
Trial: 30950565
Drug: GSK3008356 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 single doses (5 to 200 mg)
Trial: 30950565
Drug: GSK3008356 repeat
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 repeat doses (1, 3, and 10 mg twice daily for 14 days)
Trial: 30950565
Drug: GSK3008356 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 single doses
Trial: 30950565
Drug: GSK3008356 repeat
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 repeat doses
Trial: 30950565
Drug: GSK3008356 higher
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3008356 higher doses
Trial: 27092862
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CT) plus treatment as usual (TAU)
Trial: 19735515
Drug: Hydrating gel-cream
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrating gel-cream (active product)
Trial: 19735515
Drug: Gel-cream without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel-cream without active substances (placebo)
Trial: 17317205
Drug: Pegfilgrastim (6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Primary Prophylaxis (PP)
Trial: 17317205
Drug: Pegfilgrastim (6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6mg single dose on day 2 of FEC-100) - Secondary Prophylaxis (SP)
Trial: 9815633
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 180, 270, and 400 mg/m2 t.i.d.
Trial: 9815633
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at doses of 400 mg/m2 t.i.d.
Trial: 9815633
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (PPS) administered orally (p.o.) at various doses.
Trial: 8230266
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg/d orally for 2 years
Trial: 2439786
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bisoprolol
Trial: 29939421
Drug: Euglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemic clamp (5-6 mmol/l)
Trial: 29939421
Drug: Hyperglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemic clamp (9-10 mmol/l)
Trial: 26214555
Drug: Fluvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (10 mg daily)
Trial: 26214555
Drug: Valsartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (20 mg daily)
Trial: 26214555
Drug: Fluvastatin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin and Valsartan combination (10 mg and 20 mg)
Trial: 20046171
Drug: Ultrasonic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic therapy (UST)
Trial: 3613693
Drug: Sulpiride 200
RxNorm normalized name: sulpiride 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 200 mg
Trial: 15107193
Drug: Sulpiride 400
RxNorm normalized name: sulpiride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 400 mg
Trial: 12421850
Drug: [6S]-5-methyltetrahydrofolate (113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [6S]-5-methyltetrahydrofolate (113 micro g/d)
Trial: 12421850
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (100 micro g/d)
Trial: 10604083
Drug: Treatment responders
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment responders (n=21)
Trial: 25834203
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ‐SC) monotherapy, 162 mg every 2 weeks (q2w)